Nautilus Gains on Strategic Review By Investing.com

After-Hours Stock Movers:

9 Meters Biopharma Inc (NASDAQ:) 42% HIGHER; announced today positive final results from the Phase 2 study of vurolenatide and the outcome from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Vurolenatide is a proprietary long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS). Based on the outcome from the meeting and the Phase 2 data, 9 Meters intends to finalize the Phase 3 protocol in collaboration with the FDA during the fourth quarter. Clinical plans and activities are currently underway to facilitate initiation of the study upon protocol finalization. The company plans to provide further details on the Phase 3 vurolenatide clinical development program following protocol finalization.

Nautilus Group Inc (NYSE:) 6% HIGHER; announced that its Board launched a comprehensive review of strategic alternatives, which may include a potential sale of the company, to identify opportunities to accelerate the companys digital transformation under its previously announced North Star plan and enhance shareholder value.

Corvus Pharmaceuticals, Inc. (NASDAQ:) 5% HIGHER; announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation of the China National Medical Products Administration. The study will be conducted by Angel Pharmaceuticals Ltd. (Angel Pharma), Corvus’ partner in China. Mupadolimab is a humanized monoclonal antibody designed to be directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers (HNSCC).

Exicure (NASDAQ:) 5% HIGHER; announced plans to restructure the company and align resources to continue exploring strategic alternatives that maximize stockholder value

Splunk (NASDAQ:) 3% HIGHER; announced that Jason Child, Splunks CFO since 2019, has accepted a position at a leading pre-IPO semiconductor company. Reaffirms outlook.

VOXX International Corporation (NASDAQ:) 1% HIGHER; President & CEO, Patrick Lavelle, bought 13,500 shares on 09/23/22 at $6.8167.